JP2023542137A5 - - Google Patents

Info

Publication number
JP2023542137A5
JP2023542137A5 JP2023517314A JP2023517314A JP2023542137A5 JP 2023542137 A5 JP2023542137 A5 JP 2023542137A5 JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023542137 A5 JP2023542137 A5 JP 2023542137A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
area
vitiligo
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542137A (ja
Filing date
Publication date
Priority claimed from US17/023,269 external-priority patent/US20210030672A1/en
Application filed filed Critical
Priority claimed from PCT/US2021/071479 external-priority patent/WO2022061351A1/en
Publication of JP2023542137A publication Critical patent/JP2023542137A/ja
Publication of JP2023542137A5 publication Critical patent/JP2023542137A5/ja
Pending legal-status Critical Current

Links

JP2023517314A 2020-09-16 2021-09-16 白斑の局所処置 Pending JP2023542137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/023,269 US20210030672A1 (en) 2019-06-10 2020-09-16 Topical treatment of vitiligo by a jak inhibitor
US17/023,269 2020-09-16
PCT/US2021/071479 WO2022061351A1 (en) 2020-09-16 2021-09-16 Topical treatment of vitiligo

Publications (2)

Publication Number Publication Date
JP2023542137A JP2023542137A (ja) 2023-10-05
JP2023542137A5 true JP2023542137A5 (cg-RX-API-DMAC10.html) 2024-08-30

Family

ID=78135236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517314A Pending JP2023542137A (ja) 2020-09-16 2021-09-16 白斑の局所処置

Country Status (6)

Country Link
US (2) US20230364095A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213800A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023542137A (cg-RX-API-DMAC10.html)
CN (1) CN116261447A (cg-RX-API-DMAC10.html)
CA (1) CA3195357A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022061351A1 (cg-RX-API-DMAC10.html)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EA202091303A3 (ru) * 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
KR20160042064A (ko) * 2013-08-09 2016-04-18 군제 가부시키가이샤 골 재생 재료 키트, 페이스트상 골 재생 재료, 골 재생 재료 및 골 접합재
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
US20170266289A1 (en) * 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
WO2017031067A2 (en) * 2015-08-14 2017-02-23 The Trustees Of Columbia University In The City Of New York Biomarkers for treatment of alopecia areata
EP3555138A1 (en) * 2016-12-16 2019-10-23 Université de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US11957931B2 (en) * 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
BR112020013976A2 (pt) * 2018-01-09 2020-12-08 Dermavant Sciences GmbH Composições farmacêuticas para pele tópicas que contêm cerdulatinibe e usos das mesmas
US20210030672A1 (en) * 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor

Similar Documents

Publication Publication Date Title
JP2022545568A5 (cg-RX-API-DMAC10.html)
US6524623B1 (en) Therapeutic compositions and methods of use thereof
Quiroz-Mercado et al. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
EP2533785B1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
JP7532511B2 (ja) Jak阻害剤による尋常性白斑の局所治療
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP2024105436A5 (cg-RX-API-DMAC10.html)
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
HUE034886T2 (hu) Gyógyszerek cranialis adagolása
US20120083452A1 (en) Topical Anesthetic Uses of Szeto-Schiller Peptides
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
CA3146811A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
WO2000021531A1 (en) Remedies for ocular diseases
HUP0100599A2 (hu) Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen
Ezz Eldawla et al. Evaluation of efficacy of microneedling and topical methotrexate versus microneedling and topical 5-Flourouracil in treatment of vitiligo patients
US20190054045A1 (en) Methods and compositions for treating skin conditions
KR20190134807A (ko) 중추 신경계의 퇴행성 질환 및/또는 리소솜 저장병을 예방 및/또는 치료하기 위한 신규한 조성물
CN121775001A (zh) 一种b族维生素及其在制备治疗白癜风病药物、保健食品和膳食营养补充剂中的应用
Paller et al. 40. Efficacy and Safety of Dupilumab in Children Aged≥ 6 Months to< 6 Years with Moderate-to-Severe Atopic Dermatitis
MD1910Z (ro) Metodă de tratament al paraliziei nervului facial
WO1995023580A1 (en) Preventive and remedy for secondary depilation
WO2001056606A1 (en) Remedies for ophthalmic diseases
US20230364095A1 (en) Topical treatment of vitiligo
JP2006509773A (ja) 持続性アレルギー性鼻炎の治療のためのレボセチリジンの使用
Jin et al. Effect of recombinant human growth hormone add on therapy on acute stroke outcome